et al (2015) Oncol Lett.
The Food and Drug Administration (FDA) Its not completely clear how semaglutide reduces these risks
Retatrutide, if approved in future, would represent a potential addition to this landscape but that determination rests on the outcome of ongoing phase 3 research and subsequent regulatory review by the MHRA and EMA

Common GI side effects (affecting more than 1 in 10 people) according to the SmPC: Nausea : The most frequent side effect, reported in approximately 44% of patients in clinical trials, usually most pronounced during the first few weeks and with dose increases Diarrhoea : Affects roughly 30% of users, typically mild to moderate and transient Vomiting : Occurs in about 24% of patients, often associated with eating too quickly or consuming large portions Constipation : Reported in approximately 24% of users, which may require dietary modification or occasional laxative use Abdominal pain or discomfort : Affects around 20% of patients, usually described as cramping or bloating Dyspepsia and reflux : Indigestion and heartburn occur in approximately 9% of users Less common but significant GI effects : Delayed gastric emptying : Whilst this is the intended pharmacological effect, in some cases it can cause persistent nausea, vomiting, and inability to tolerate food Pancreatitis : Has been reported in clinical trials and post-marketing

This powerful supplement is designed to optimize your bodys ability to absorb essential vitamins
Due to safety concerns, Dr, Friedman only prescribes compounded GLP1s (Tirzepatide and Semaglutide ) that are FDA-approved